Newsroom
Latest Press Releases
Arch Oncology to Present at 39th Annual J.P. Morgan Healthcare Conference
BRISBANE, CA and ST. LOUIS, MO, January 6, 2021 – Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, today announced that Julie Hambleton, M.D., the Company’s Interim President and Chief Executive Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference.
Arch Oncology Announces First Patient Dosed in Phase 1/2 Clinical Trial of Anti-CD47 Antibody AO-176 in Multiple Myeloma
BRISBANE, CA and ST. LOUIS, MO, December 7, 2020 – Arch Oncology, Inc., a clinical-stage immuno-oncology company announces first dedicated clinical trial of an Anti-CD47 Antibody in Multiple Myeloma at ASH 2020, new preclinical data presented on AO-176 in Multiple Myeloma
Arch Oncology Presents New Preclinical Data on Highly Differentiated Anti-CD47 Antibody AO-176 at ASH 2020
BRISBANE, CA and ST. LOUIS, MO, December 6, 2020 – Arch Oncology, Inc., a clinical-stage immuno-oncology company Presents New Preclinical Data on Highly Differentiated Anti-CD47 Antibody AO-176 at ASH 2020
Arch Oncology Appoints Ronald Krasnow, Esq. as Chief Operating Officer
BRISBANE, CA and ST. LOUIS, MO, November 16, 2020 – Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, appoints Ronald Krasnow, Esq. as Chief Operating Officer.
Arch Oncology to Present New Preclinical Data on Highly Differentiated Anti-CD47 Antibody AO-176 at SITC 2020
BRISBANE, CA and ST. LOUIS, MO, November 9, 2020 – Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, today announced announced the presentation of new preclinical data on AO-176 at the SITC Annual Meeting 2020.
Arch Oncology to Present at Upcoming Conferences
BRISBANE, CA and ST. LOUIS, MO, October 26, 2020 – Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, today announced upcoming presentations at conferences and medical meetings.
Arch Oncology Advances Anti-CD47 Antibody AO-176 into Chemotherapy Combination Phase 1/2 Trial in Solid Tumors
BRISBANE, CA and ST. LOUIS, MO, October 5, 2020 – Arch Oncology Advances Anti-CD47 Antibody AO-176 into
Chemotherapy Combination Phase 1/2 Trial in Solid Tumors. Citing Encouraging Safety and Anti-tumor Activity for
AO-176 Monotherapy in Phase 1 Trial, They are Expanding into Chemotherapy Combination Phase 1/2 Trial.
Arch Oncology Announces Formation of Scientific Advisory Board
BRISBANE, CA and ST. LOUIS, MO, June 22, 2020 – Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of best-in-class anti-CD47 antibody therapies, today announced today the formation of a Scientific Advisory Board (SAB) and appointment of five leading oncology experts.
Arch Oncology Appoints Biotechnology Industry Veteran Julie Hambleton, M.D. to Board of Directors
BRISBANE, CA and ST. LOUIS, MO, April 21, 2020 – Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of best-in-class anti-CD47 antibody therapies, today announced the appointment of Julie Hambleton to the Company’s Board of Directors.
Arch Oncology Appoints Drew Dennison to Board of Directors
BRISBANE, CA and ST. LOUIS, MO, August 12, 2019 – Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of best-in-class anti-CD47 antibody therapies, today announced the appointment of Drew Dennison to Board of Directors.
Publications
Novel SIRPα Antibodies That Induce Single-Agent Phagocytosis of Tumor Cells while Preserving T Cells
Publication: The Journal of Immunology.
Authors:
, , , , , andDevelopment of AO-176, a Next-Generation Humanized Anti-CD47 Antibody with Novel Anticancer Properties and Negligible Red Blood Cell Binding
Publication: Molecular Cancer Therapeutics. Published first online on December 26, 2019.
Authors: Robyn J. Puro, Myriam N. Bouchlaka, Ronald R. Hiebsch, Benjamin J. Capoccia, Michael J. Donio, Pamela T. Manning, William A. Frazier, Robert W. Karr, and Daniel S. Pereira
Poster Presentations
ASH Annual Meeting and Exposition 2020
Poster Presentation: AO-176, a Highly Differentiated Clinical Stage Anti-CD47 Antibody, Exerts Potent Anti-Tumor Activity in Preclinical Models of Multiple Myeloma as a Single Agent and in Combination With Approved Therapeutics
ASH Annual Meeting and Exposition 2020
Poster Presentation: Pre-clinical Combination of AO-176, a Highly Differentiated Clinical Stage CD47 Antibody, with Either Azacitidine or Venetoclax Significantly Enhances DAMP Induction and Phagocytosis of Acute Myeloid Leukemia
ASH Annual Meeting & Exposition 2019
Poster Presentation: Highly Differentiated Anti-CD47 Antibody AO-176, Potently Inhibits Hematologic Malignancies Alone and in Combination in Pre-Clinical Models
SITC Annual Meeting 2019
Poster Presentation: Novel SIRP Antibodies with Differentiated Characteristics for Targeting Innate Immunity in Cancer
AACR-NCI-EORTC EORTC International Conference on Molecular Targets and Cancer Therapeutics 2019
Poster Presentation: AO-176, a highly differentiated humanized anti-CD47 antibody, exhibits single-agent and combination anti-tumor efficacy with chemotherapy and targeted antibodies in preclinical models (Abstract #: B100)
AACR Annual Meeting 2019
Poster Presentation: AO-176, a normal cell sparing humanized anti-CD47 antibody
AACR Annual Meeting 2019
Poster Presentation: Evaluation of novel anti-SIRP antibodies as potential cancer therapeutics
ASH Annual Meeting & Exposition 2018
Poster Presentation: Therapeutic potential of AO-176, a next-generation humanized CD47 antibody, for hematologic malignancies
EORTC-NCI-AACR Symposium 2018
Poster Presentation: Development of AO-176, a next-generation humanized anti-CD47 antibody with novel anti-cancer properties and negligible binding to red blood cells
SITC Annual Meeting 2018
Poster Presentation: AO-176, next-generation CD47 antibody, induces immunogenic cell death